Background. Although it is evident that zoster vaccination reduces postherpetic neuralgia (PHN) risk by reducing herpes zoster (HZ) occurrence, it is less clear whether the vaccine protects against PHN among patients who develop HZ despite previous vaccination.
Prevention Study (SPS) demonstrated that the use of the zoster vaccine reduced the burden of illness due to HZ by 61.1%, and the incidence of PHN by 66.5% [9] . A study among the Medicare population showed that the effectiveness of zoster vaccines against incidence of zoster and PHN is 48% and 59%, respectively [10] . The lower risk of PHN in the vaccinated population resulted mainly from the lower risk of HZ with vaccination.
Although it is clear that zoster vaccination is associated with a reduced risk of PHN because it reduces the occurrence of HZ, one common but unanswered question since licensure of the vaccine is whether someone who develops HZ despite being vaccinated has a lower risk of PHN than if she or he had never been vaccinated. Data from the SPS suggested some incremental benefit for the vaccine in preventing PHN among subjects who developed HZ despite vaccination. Among vaccinated SPS participants who later developed HZ, the risk of developing PHN was 8.5%, compared with 12.5% in the unvaccinated participants who developed HZ [9] . Further examination suggests that the reduced risk of developing PHN was significant only in patients aged ≥70 years (9.8% in vaccinated vs 18.5% in unvaccinated patients) [9] .
Postlicensure studies offer opportunities to examine this less common outcome, which requires larger samples sizes of vaccinated patients with HZ, and to examine how vaccines perform under conditions of community use. In this cohort study, we aimed to evaluate whether patients who developed HZ despite having been vaccinated had a reduced risk of developing PHN.
METHODS

Setting
The study was conducted among members of Kaiser Permanente Southern California (KPSC), an integrated healthcare system that provides comprehensive prepaid health services for its 3.9 million members. Members are racially diverse, and >99% are community-dwelling. The demographic makeup of the KPSC membership closely mirrors that of the Southern California population [11, 12] . Compared with the racial/ethnic distribution of the United States population, the KPSC membership has twice as many individuals of Asian descent and 3 times as many Hispanics. Data regarding demographics, services, and diagnoses were tracked in KPSC electronic health records from the outpatient, emergency department, and hospital settings. Pharmacy and vaccination utilization was linked through patients' unique medical record numbers. Vaccinations received outside the health plan with appropriate documentation were also recorded.
Several factors help ensure the capture of relevant health information. HZ vaccine is provided to KPSC members at no charge, which serves as an incentive for members to receive immunizations within the system. There was also a very strong motivation for members to use services internally, because KPSC is a prepaid system. In addition, data collected during clinical care from non-KPSC providers were likely to be captured in KPSC databases because documentation of outside visits was required for reimbursement of such services by KPSC. Thus, the capture of care delivered to the members by electronic administrative data was reasonably assumed to be very comprehensive.
Study Participants
We identified a list of adults who were vaccinated against HZ at age ≥60 years after 1 January 2007 and had an episode of HZ after vaccination. Five potential unvaccinated patients with HZ were matched to each vaccinated patient with HZ for sex and date of birth (within 1 year). Diagnosis of HZ was identified from the outpatient setting by the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes 053.xx. An index date, the date of HZ vaccination for the vaccinated patient, was also assigned to the matched unvaccinated patients. All patients with HZ were required to have ≥1 year of continuous membership in KPSC before the index date and ≥6 months continuous membership before and after the HZ diagnosis. All patients with HZ had had no HZ diagnosis within 1 year before the index date. Because HZ vaccination is not recommended for immunocompromised patients, we excluded such patients from the study, defining them as those who had a diagnosis of human immunodeficiency virus infection, leukemia, or lymphoma or had received immunosuppressive agents within 1 year before the index date; patients who became immunocompromised after the index date were included in our analysis [13] .
PHN Definition
HZ-related pain was identified as pain consistent with the HZ episode, not explained by other obvious causes (eg, rheumatoid arthritis). PHN was defined as any encounter for HZ-related pain >3 months after initial HZ diagnosis. Trained medical residents conducted targeted reviews of the full medical record, including prescribed medications, for each participant identified from the study population to determine the presence HZrelated pain 1, 2, 3, and 6 months after HZ diagnosis, based on clinical judgment. We included the first medical encounter beyond the 6-month window to capture HZ-related pain throughout the entire 6 months.
The residents were supplied with a random sample of medical record numbers and the dates of initial HZ diagnosis of each matched set (1 vaccinated and 5 unvaccinated patients with HZ) from the study population. Reviewers were not masked as to vaccination status because this could have been noted in the medical record. The residents then reviewed the medical record of a pair including 1 vaccinated patient with HZ and 1 of the unvaccinated patients with HZ who was randomly selected from the 5. If the medical record suggested that the HZ was recurrent, if there was evidence of a positive herpes simplex virus culture or of chronic rash, or HZ was not diagnosed, then the patient was excluded. If an unvaccinated subject was excluded, the next matched subject was selected for the vaccinated subject. The residents performed the review until 1200 pairs of patients with HZ had been reached.
For each study participant, we assessed clinical characteristics related to the initial HZ episode, including the following: date of the episode, days from onset of rash to the date of visit for episode, affected dermatomes, location of rash, rash characteristics, whether or not there was a positive culture result for the varicella zoster virus, whether or not the diagnosis was made by a dermatologist or infectious disease specialist, and whether or not an antiviral prescription was given for the episode. We included information regarding the HZ episode from all medical encounters up to 30 days before and after the initial HZ date, to capture as much relevant clinical information pertaining to the HZ episode of interest as possible. For example, the date of the ICD-9-CM code that was originally identified may not have represented the first clinical visit for symptoms of the HZ episode of interest. Likewise, visits that occurred soon after the initial HZ date may have captured laboratory results that were not available on the HZ diagnosis date itself.
Data were collected on all medical encounters, including phone calls or emails (eg, to request prescriptions or refills). All medical encounters, including those that did not mention any conditions related to HZ, were reviewed and included to assess overall healthcare-seeking behavior during the 6-month period.
Other covariates, such as sex, race (self-reported), healthcare utilization (defined as the number of hospitalizations or outpatient or emergency department visits within 6 months before the initial HZ diagnosis date), and chemotherapy within 6 months before the initial HZ diagnosis date were collected using electronic medical records.
Statistical Analyses
Matched pairs with HZ cases occurring within 1 month of the index date were excluded from the analysis [9] . Baseline characteristics, clinical characteristics of the HZ episode, and medical encounters in the 6 months after the HZ episode were compared between the vaccinated and the unvaccinated patients. Negative binomial models were used to estimate the relative risk (RR) and 95% confidence intervals (CI) for pain (yes/no) 90 days after the initial HZ diagnosis (defined as PHN), comparing the vaccinated and the unvaccinated cohorts, with adjustment for age at HZ, race, calendar year of HZ diagnosis, antiviral or corticosteroid prescription at initial HZ diagnosis, visit for HZ within 3 days of rash onset, and receipt of chemotherapy and healthcare utilization (outpatient visits, emergency department visits, and hospitalizations) in the 6 months before HZ diagnosis. Age-and sex-specific RRs were also estimated, adjusted for the other variables mentioned above. SAS Enterprise Guide software (version 4.2; SAS Institute) was used for all analyses.
The protocol was reviewed and approved by the KPSC Institutional Review Board. The requirement for informed consent was waived because there was no patient contact.
RESULTS
Of the 1200 matched pairs of patients with HZ, 45 pairs were excluded because HZ occurred within 1 month of the index date, leaving 1155 pairs of patients with HZ for analysis. The distribution of baseline characteristics of the patients with HZ by vaccination status is presented in Table 1 . About two-thirds (62.6%) of the study participants were female. The age distribution was comparable between groups; about 60% of the patients with HZ were aged ≥70 years at the index date. The distribution of race differed between the vaccinated and unvaccinated cohorts (69.7% white in the vaccinated vs 49.3% white in the unvaccinated). The number of outpatient visits during the 6 months before the first visit for HZ was higher for the vaccinated than for the unvaccinated cohort (mean, 4.1 vs 3.5 visits), but the number of emergency department visits and hospitalizations showed no difference. For the vaccinated cohort, the mean period of time from vaccination to first visit for HZ was 692.5 days, compared with 471.8 days for the unvaccinated cohort. Table 2 presents the clinical characteristics and treatment of the initial HZ episode by vaccination status. Approximately 50% of patients were seen for their HZ rash within 3 days of rash onset ,and this did not vary by vaccination status or sex. More than 80% of the medical records lacked information on dermatome. The vaccinated group had a smaller proportion of patients with rash on the chest. Close to 90% of the records indicated that patient's rash was unilateral, with the remaining records not describing laterality. More than two-thirds of the records described the rash as vesicular, and this description was more common in the unvaccinated patients (73.3% vs 67.7%). Most patients were prescribed antiviral treatment. Treatment was slightly more common in the unvaccinated patients and did not vary by sex. The HZ diagnosis was uncertain more frequently in vaccinated than in unvaccinated patients with HZ. Table 3 reports the medical encounters during the 6-month period after the initial HZ visit. The vaccinated patients had a mean of 8.5 encounters, versus 7.7 in the unvaccinated patients. The vaccinated cohort had fewer encounters for HZ-related pain than the unvaccinated group (mean, 0.8 vs 1.2, excluding the initial visit for HZ; P < .01). Furthermore, for women the mean number of visits was 1.3 for unvaccinated and 0.8 for vaccinated patients. In contrast, for men the mean number was 0.8 for unvaccinated and 1.0 for vaccinated patients. Unvaccinated men had significantly fewer visits than unvaccinated women (mean, 0.8 vs 1.3; P < .05). Table 4 presents HZ-related pain in the 6 months after HZ diagnosis by sex and by vaccination status. In men, 47 (10.9%) of the vaccinated patients had visits for HZ-related pain occurring >1 month after the initial visit, compared with 65 (15.0%) of the unvaccinated patients. The proportions of vaccinated versus unvaccinated men with visits mentioning HZ-related pain more than 2, 3, and 6 months after the initial HZ diagnosis were 8.6% versus 9.0%, 6.0% versus 5.8%, and 
DISCUSSION
The SPS has demonstrated that zoster vaccine reduces the risk of PHN among the vaccinated by reducing HZ occurrence [9] . It also demonstrated that zoster vaccine reduced the risk of PHN among vaccinated persons who developed HZ, particularly in vaccine recipients aged ≥70 years. Our study confirms the findings in a more broadly representative population and suggests that HZ vaccination provides incremental benefits beyond simply reducing HZ incidence.
Based on medical encounters for HZ-related pain occurring ≥3 months after the initial HZ visit to define PHN, our results suggest that female patients who develop HZ despite vaccination had a lower risk of PHN than unvaccinated female patients with HZ. We found this benefit in both 60-69-and ≥70-year age groups. The vaccine seems most effective in preventing the most prolonged episodes of PHN, confirming the results noted in the SPS. Comparing vaccinated and unvaccinated female patients, the reductions in the RR of HZ-related pain were greater for HZ-related pain of longer duration (RR, 0.6, 0.4, 0.4, and 0.2 for pain at 1, 2, 3, and 6 months, respectively). This finding is clinically important because patients and providers may be more likely to consider vaccination if it can prevent the most prolonged episodes of PHN. The data suggest that the pathways by which HZ vaccination interferes with development of HZ (ie, boosted cell-mediated immunity), though not sufficient to prevent all HZ, may reduce the severity and duration of the HZ episodes that do occur.
We did not observe a reduced risk of PHN associated with vaccination among men in any age group. This striking sexspecific difference could be random error because of the small number of PHN cases, caused by an unrecognized biological phenomenon, or related to differential healthcare-seeking behavior by sex. Almost all patients seek medical care for acute HZ, regardless of sex [14, 15] . Patients may be particularly concerned about the symptoms of this condition with its acute onset of unilateral pain and dysesthesias. If they do recognize the symptoms of HZ, they may also realize that the condition needs to be promptly treated. Electronic health data regarding medically attended HZ may therefore represent a sensitive proxy for actual HZ [14] , particularly in a medical setting such as KPSC, with its prepaid healthcare and easy access.
On the other hand, if pain persists and PHN develops, healthcare-seeking behavior may change, particularly because treatments for PHN pain are often inadequately effective and associated with adverse effects. As patients become aware of the source of the pain over time, many may not bother with clinic appointments or medication refills. Healthcare-seeking behavior might become more variable, resulting in opportunities for confounding (ie, when vaccination and healthcare-seeking behaviors are correlated). There is, for instance, substantial documentation that among patients with chronic pain, women are more likely to seek medical care and request medications [16] [17] [18] [19] . Indeed, among unvaccinated patients in our study, men had fewer visits for PHN (≥3 months of HZ-related pain) than women (5.8% vs 10.4%), whereas for unvaccinated subjects in the SPS, which used active surveillance to inquire about subjects' pain, men were more likely than women to report HZ-related pain after 3 months (14.1% vs 10.3%) [9] . Furthermore, in one of our ongoing studies where HZ-related pain is identified by interviewing patients using the Zoster Brief Pain Inventory, as in the SPS, the incidences of HZ-related pain in unvaccinated men were 31.8%, 20.7%, and 13.9% at 1, 2, and 3 months after HZ diagnosis. The incidence of PHN defined by medical encounter among unvaccinated men in the current study (5.8%) is significantly lower than that defined by inquiry (13.9%). This difference is less pronounced in unvaccinated women (10.4% vs 11.4% for PHN incidence defined by encounter vs inquiry [20] ). Defining PHN using healthcare encounters as evidence of pain, rather than using self-reported HZ pain, could underestimate the incidence of PHN and potentially introduce confounding if vaccinated and unvaccinated individuals have different healthcare-seeking behavior for chronic pain. One should be cautious about comparing findings from studies using medically attended PHN (ie, using electronic medical records) as the end point with findings from studies using self-reported PHN because different methods for PHN ascertainment could lead to different estimates of PHN incidence and vaccine effectiveness for preventing PHN. Further studies comparing self-reported HZ pain with healthcare seeking by sex, vaccination status, and other factors would help elucidate potential confounders. If the sex-specific results are due to a true biological phenomenon (ie, differential HZ-vaccine immunogenicity), this would have implications in terms of basic biology and vaccine policy. From a healthcare utilization perspective, our results show that when HZ occurs those who have been vaccinated with the zoster vaccine have fewer visits for HZ-related pain, at least among women.
Some potential limitations deserve mentioning. Although we made efforts to correctly identify incident HZ in vaccinated and unvaccinated groups by excluding cases of recurrent HZ, herpes simplex, or other chronic rashes, some misclassification may have occurred. In another study, we found that 85% of clinically diagnosed cases were confirmed as HZ by polymerase chain reaction testing [21] . We were also unable to assess severity of pain because it was not consistently recorded in the medical record. Furthermore, the documentation of pain or discomfort in the record was sometimes not clear; in these instances, the physicians reviewing the records had to make subjective determinations. In addition, although residents were instructed not to look for vaccination history, it was documented in the records and some reviews may have been unmasked as to vaccination status. Finally, patients with more healthcare encounters were more likely to have evidence of HZ-related pain. This pattern could bias the estimate of association toward the null because vaccinated individuals tended to visit physicians more frequently.
In conclusion, we provide evidence that HZ vaccination yields benefits beyond simple prevention of HZ. Furthermore, the vaccine is most effective at preventing the most prolonged episodes of PHN. Although uptake of HZ vaccine was low after introduction of the vaccine, rates have more recently started to increase. Ideally, as physicians and patients recognize the full benefits of HZ vaccination, more persons will take advantage of the vaccine to decrease the risk of long-term pain and potential disability.
